What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **Identify reliable predictors for achieving hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B virus (HBV) infection after receiving pegylated interferon - alpha (PegIFN - alpha) treatment**. ### Problem Background Chronic hepatitis B virus (HBV) infection is a global public health problem. According to the World Health Organization (WHO), approximately 296 million people are suffering from chronic HBV infection, and the number of new infections reaches 1.5 million every year. Chronic hepatitis B (CHB) can lead to liver fibrosis, cirrhosis, hepatocellular carcinoma and premature death, and is associated with an increased risk of multiple cancers. Without appropriate treatment, it is expected that the number of hepatitis B - related deaths will reach 1.14 million by 2035. In China, the number of chronic HBV - infected people was estimated to be about 80 million in 2022, ranking first among the global HBsAg - positive population. ### Research Objectives The ideal treatment goal is to achieve HBsAg seroclearance or seroconversion, which is regarded as a functional cure. However, the spontaneous HBsAg seroclearance rate in adult CHB patients is only 1.17% per year, and it is even lower in children. Current antiviral drugs include interferon - alpha (including conventional interferon - alpha and pegylated interferon - alpha) and nucleoside (acid) analogues (NAs). Studies have shown that PegIFN - alpha - based therapies significantly improve the functional cure rate. For example, in inactive HBsAg carriers, PegIFN - alpha - based therapies achieve a high HBsAg seroclearance rate of 47%, while the control group is only 1.54%. ### Research Methods In order to systematically summarize these predictors, the research team conducted a systematic literature search and meta - analysis, covering relevant literatures in the Cochrane Library, Embase, PubMed and Web of Science databases from the establishment of the databases to September 28, 2022. The meta - analysis was carried out in accordance with the PRISMA statement, and baseline characteristics and indicators during the treatment process were evaluated as predictors of HBsAg seroclearance. ### Main Findings A total of 27 studies were included in the study, involving 7,913 patients. The results showed that multiple factors were independently associated with PegIFN - alpha - based therapy - induced HBsAg seroclearance, including: - **Age**: For each additional year of age, the probability of HBsAg seroclearance decreases (OR = 0.961, 95% CI 0.925 - 0.997) - **Gender**: Males are more difficult to achieve HBsAg seroclearance than females (OR = 0.537, 95% CI 0.371 - 0.777) - **Genotype**: Genotype A is more likely to achieve HBsAg seroclearance than genotypes B/D (A vs. D: OR = 10.738, A vs. D: OR = 7.472) - **Treatment strategy**: Combination therapy is more likely to achieve HBsAg seroclearance than single - drug therapy (OR = 2.126) - **Baseline HBV DNA level**: A lower baseline HBV DNA level is associated with a higher HBsAg seroclearance rate (OR = 0.414) - **Baseline HBsAg level**: A lower baseline HBsAg level is associated with a higher HBsAg seroclearance rate (OR = 0.373) - **HBsAg levels and the magnitude of decline at week 12 and week 24 of treatment**: The lower the HBsAg levels or the greater the magnitude of decline at week 12 and week 24 of treatment, the higher the probability of HBsAg seroclearance - **ALT elevation**: ALT elevation at week 12 of treatment is also a strong predictor of HBsAg seroclearance (OR = 3.622) ### Conclusions This is the first time that predictors of HBsAg seroclearance in PegIFN - alpha - based therapies, including baseline and treatment - process factors, have been identified through meta - analysis. These findings are helpful for developing better comprehensive prediction models, guiding individualized treatment, achieving the highest cost - effectiveness ratio, and thus improving the treatment effect of PegIFN - alpha. ### Formula Presentation - Relationship between age and HBsAg seroclearance: \[ OR_{\text{age}} = 0.961, \quad 95\% \, CI = [0.925, 0.997] \] - Relationship between gender and HBsAg seroclearance (male vs. female): \[

Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis

Recurrence and Influencing Factors of Hepatitis B Surface Antigen Seroclearance Induced by Peginterferon Alpha-Based Regimens

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Predictive Model for HBsAg Clearance Rate in Chronic Hepatitis B Patients Treated with Pegylated Interferon Α-2B for 48 Weeks

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance

Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis

Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon Α-2A in HBeAg-Negative Chronic Hepatitis B.

Systematic review with network meta-analysis: sustained hepatitis B surface antigen clearance after pegylated interferon cessation

Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy

Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.

Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis

The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.